Aldeyra Therapeutics, Inc. (ALDX)

Market Cap	132.97M
Revenue (ttm)	n/a
Net Income (ttm)	-57.70M
Shares Out	59.90M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	411,352
Open	2.200
Previous Close	2.200
Day's Range	2.170 - 2.250
52-Week Range	1.140 - 7.200
Beta	0.90
Analysts	Strong Buy
Price Target	9.50 (+327.93%)
Earnings Date	May 14, 2025

About ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 2, 2014
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: ALDX
• Website: https://www.aldeyra.com

Analyst Forecast

According to 2 analysts, the average rating for ALDX stock is "Strong Buy." The 12-month stock price forecast is $9.5, which is an increase of 327.93% from the latest price.

Price Target

$9.5

(327.93% upside)

Analyst Consensus: Strong Buy